Skip to main content

Psoriasis Content

FDA Alerts
The FDA has recently approved a new once-daily topical treatment for adult patients with plaque psoriasis.
News
A recent study demonstrated the safety and long-term effectiveness of bimekizumab, with participants maintaining high PASI scores through 60 weeks of treatment.
News
Findings from a recent study showed that satisfaction with physicians is associated with mental health comorbidities among patients with psoriasis.
News
Using data from a large registry, researchers investigated the real-world safety of several systemic medications including etanercept, secukinumab, ustekinumab, and apremilast.
NPF Endorsed Features, Partners
Lauren Mateja, Managing Editor
Patients with psoriasis and psoriatic arthritis have increased calls to their dermatologist for advice on continuance of their therapy during uncertain times. Guidance from national organizations provide answers that dermatologists can pass on to their patients.
Derm Q&A
Melissa Weiss, Associate Editor
Psoriasis is associated with many comorbid conditions. In an interview with The Dermatologist, Ronald Prussick, MD, discusses the latest research on these comorbidities, evidence on lifestyle and treatment options that could potentially prevent or manage both psoriasis and comorbid conditions, and the importance of screening and aggressively treating psoriatic arthritis.
News
Findings from a recent systemic review showed some biologic medications may be effective for patients with erythrodermic psoriasis.
NPF Endorsed Features, Partner Resource, Partners
Lauren Mateja, Managing Editor
New and emerging therapies such as biologics continue to improve quality of life and outcomes for patients with psoriasis. Biologics that block IL-23 functions present a unique opportunity to provide long-term, effective treatment.
News
A recent meta-analysis highlighted several biologics that were associated with higher short-term and long-term PASI 75, PASI 90, and PASI 100 response rates.
News
Findings from a recent study showed an NK1 receptor antagonist may be an effective, new option for patients with psoriatic pruritus.
Back to Top